FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-0287									
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

						3600	1011 30(11) C	JI 111E	invesimen	il Cui	npany Act o	1 1940							
1. Name and Address of Reporting Person*  Johnson Jason K					<u>CC</u>	2. Issuer Name <b>and</b> Ticker or Trading Symbol  COMMUNITY HEALTH SYSTEMS INC  CYH ]								5. Relationship of Reporting I (Check all applicable) Director  Officer (give title			Person(s) to Issuer  10% Owner Other (specify		
(Last) (First) (Middle) 4000 MERIDIAN BOULEVARD						3. Date of Earliest Transaction (Month/Day/Year) 03/01/2022								below)  SVP & CAO					
(Street) FRANKLIN TN 37067				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person						
(City)	(Sta	ate) (.	Zip)										Form filed by More than One Reporting Person						
		Tab	le I - Noi	n-Deriv	/ative	e Se	curities	s Ac	quired,	Dis	posed of	, or Ben	eficia	lly Owned					
			2. Transaction Date (Month/Day/Yea		Execution Date,		Code (Instr.					Beneficia Owned F	es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	(A) or (D)	Price	Transact	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)	
Common Stock				03/03	3/01/2022				A		25,000(1	0 <sup>(1)</sup> A		00 90,	90,442		D		
Common Stock			03/03	1/2022				F		5,497	D	\$0.	00 84,	84,945		D			
		٦									osed of, o			y Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Date (Month/Day/Year)	3A. Deemee Execution I if any (Month/Day	Date,	4. Transaction Code (Instr. 8)		n of l		6. Date Exercisable Expiration Date (Month/Day/Year)		•	e and 7. Title and Al of Securities Underlying Derivative Se (Instr. 3 and 4		Derivative Security	9. Numbe derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	Owners Form: Direct ( or Indir	Ownership	Beneficial Ownershi (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisal	ole	Expiration Date	Title	Amour or Number of Shares	er					
Performance Based Restricted	\$0.00	03/01/2022			Α		25,000		(2)		(2)	Common Stock	25,00	\$0.00	25,000	0	D		
Stock Options (Right to Buy)	\$10.18	03/01/2022			A		25,000		03/01/202	3 <sup>(3)</sup>	02/29/2032	Common Stock	25,00	\$0.00	25,000	0	D		
Performance Based Restricted	\$0.00								(4)		(4)	Common Stock	15,00	00	15,000	0	D		
Performance Based Restricted	\$0.00								(5)		(5)	Common Stock	18,00	00	18,000	0	D		
Stock Options (Right to Buy)	\$4.93								03/01/202	1 <sup>(3)</sup>	02/28/2030	Common Stock	15,00	00	15,000	0	D		
Stock Options	\$8.81								03/01/202	2 <sup>(3)</sup>	02/28/2031	Common	18,00	00	18,00	0	D		

## **Explanation of Responses:**

Buy)

- 1. The time-vesting restrictions on this award of restricted stock will lapse in 1/3 increments on the first, second and third anniversary of the date of grant.
- 2. The vesting of these performance-based restricted shares is allocated to the attainment of the following pre-determined performance objectives between 1/1/2022 and 12/31/2024 (the "2022-2024 Performance objectives between 1/1/2022 and 12/31/2024). Period"), as follows: 50% to a Cumulative Consolidated Adjusted EBITDA Growth target; and 50% to a Cumulative Same-Store Net Revenue Growth target. The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each performance objective will ultimately vest on the third anniversary of the date of grant, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance objective during the 2022-2024 Performance Period.
- 3. Vesting occurs in 1/3 increments on the first, second and third anniversary of the date of grant.
- 4. The vesting of these performance-based restricted shares is subject to the attainment of certain performance objectives between 1/1/2020 and 12/31/2022 (the "2020-2022 Performance Period"). The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each applicable performance objective will ultimately vest on the third anniversary of the date of grant, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance objective during the 2020-2022 Performance Period.
- 5. The vesting of these performance-based restricted shares is subject to the attainment of certain performance objectives between 1/1/2021 and 12/31/2023 (the "2021-2023 Performance Period"). The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each applicable performance objective will ultimately vest on the third anniversary of the date of grant, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance objective during the 2021-2023 Performance Period.

## Remarks:

Christopher G. Cobb, Attorney in Fact for Jason K. Johnson

03/02/2022

\*\* Signature of Reporting Person

Date

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.